Tarina Fe 1/20 (Norethindrone Acetate and Ethinyl Estradiol Tablets, USP and Ferrous Fumarate Tab...

FDA Drug Recall #D-0860-2017 — Class III — January 30, 2017

Recall Summary

Recall Number D-0860-2017
Classification Class III — Low risk
Date Initiated January 30, 2017
Status Terminated
Voluntary Voluntary: Firm initiated

Recalling Firm

Firm Mylan Pharmaceuticals Inc.
Location Morgantown, WV
Product Type Drugs
Quantity 43,848 cartons

Product Description

Tarina Fe 1/20 (Norethindrone Acetate and Ethinyl Estradiol Tablets, USP and Ferrous Fumarate Tablets), 1 blister pack containing 28 tablets (NDC 50102-128-01), packaged in 3 pouches, each pouch contains one blister pack of 28 tablets (NDC 50102-128-03), Rx only, Manufactured for: Afaxys, Inc., Charleston, SC 29403, USA, Product of India.

Reason for Recall

Chemical Contamination: out of specification results for impurities were found to be the result of contamination of product from vapors associated with paint thinner used in repair of the manufacturing room.

Distribution Pattern

Nationwide in USA

Lot / Code Information

Lot #: 6843F002D, Exp 02/18

Other Recalls from Mylan Pharmaceuticals Inc.

Recall # Classification Product Date
D-0049-2021 Class III Candesartan Cilexetil and Hydrochlorothiazide T... Oct 2, 2020
D-1057-2020 Class III Tacrolimus Capsules, USP 5mg, 100-count bottle,... Mar 23, 2020
D-1031-2020 Class II Sotalol HCL Tablets, USP (AF) 80 mg, 100 count ... Mar 9, 2020
D-0791-2020 Class II Nizatidine Capsules, USP 150 mg, Rx Only, Mylan... Jan 7, 2020
D-0792-2020 Class II Nizatidine Capsules, USP 300 mg, Rx Only, Mylan... Jan 7, 2020

Frequently Asked Questions

Nitrosamines are probable human carcinogens — they can increase cancer risk with long-term exposure above certain thresholds, but they do not cause immediate harm from taking a single dose. The FDA calculates an acceptable daily intake (ADI) for each nitrosamine compound, and recalls are triggered when levels exceed this threshold. If you have been taking a recalled product, the FDA generally advises against abruptly stopping your medication (especially for critical conditions like blood pressure or diabetes) until you consult your doctor. The incremental cancer risk from short-term exposure is very small.

Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.

Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.

What Should You Do?

Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.